Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19.

ABSTRACT:

Background

To date, studies investigating the inflammatory bowel disease (IBD) patient experience with coronavirus disease 2019 (COVID-19) have consistently reported that the observed rate of COVID-19 within this population is similar to the general population. Limited research has suggested that corticosteroid use in the IBD population may be associated with worse COVID-19 outcomes, but it is still yet to be determined if specific IBD-related clinical factors are associated with worse outcomes. Our goal was to describe clinical COVID-19 outcomes for IBD patients and to identify the clinical factors that may be associated with worse outcomes.

Methods

In this retrospective study, we utilized the inpatient database within the largest hospital network in the New York City Metro

SUBMITTER: Sultan K 

PROVIDER: S-EPMC8734496 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature